While it is recognized that aquaporin-4 (AQP4)-specific T cells and antibodies participate in the pathogenesis of neuromyelitis optica (NMO), a human central nervous system (CNS) autoimmune demyelinating disease, creation of an AQP4-targeted model with both clinical and histologic manifestations of CNS autoimmunity has proven challenging. Immunization of wild-type (WT) mice with AQP4 peptides elicited T cell proliferation, although those T cells could not transfer disease to naïve recipient mice. Recently, two novel AQP4 T cell epitopes, peptide (p) 135-153 and p201-220, were identified when studying immune responses to AQP4 in AQP4-deficient (AQP4 -/-) mice, suggesting T cell reactivity to these epitopes is normally controlled by thymic negative selection. AQP4
Introduction
Neuromyelitis optica (NMO) is a central nervous system (CNS) autoimmune inflammatory demyelinating disease that causes recurrent episodes of paralysis and visual loss leading to permanent neurologic disability 1 . NMO is currently considered primarily to be a humoral autoimmune disease 2 as it is associated with antibodies (Igs) targeting aquaporin-4 (AQP4), a water channel expressed abundantly on astrocytes 3, 4 . However, CNS inflammation is a prerequisite for CNS entry of AQP4 Ig 5, 6 . Thus, it has not been possible to establish a model of NMO by transfer of anti-AQP4 Igs alone. The findings that (1) pathogenic AQP4-specific Igs in NMO patients are IgG1 1, 2 , a T cell-dependent Ig subclass 7 (2) T cells are identified in NMO lesions 8, 9 (3) NMO is associated with certain MHC II genes (e.g. HLA-DR17 (DRB1*0301)) 10 , and (4) proinflammatory AQP4-reactive DR-restricted Th17 cells are expanded in NMO patients 11, 12 all indicate that AQP4-specific T cells have a key role in NMO pathogenesis. Thus, it is important to develop animal models to determine how AQP4-specific T cells may contribute to NMO pathogenesis.
Several years ago, multiple AQP4 T cell epitopes were identified in wild-type (WT) mice 13, 14 and rats 15 . While it was observed that AQP4-reactive T cells could induce opticospinal inflammation in naïve recipient rats 15, 16 , significant clinical signs of CNS disease were not observed. Similarly, direct immunization of WT mice with peptides containing AQP4 T cell epitopes 14, 17 , or transfer of proinflammatory T cells targeting those determinants 17 , did not cause clinical signs or histologic evidence of CNS autoimmunity.
Recently, it was observed that immunization of C57BL/6 AQP4-deficient (AQP4 -/-) mice with AQP4 peptide (p) 135-153 or p201-220, two determinants predicted to bind MHC II (I-A b ) with high affinity 18 , elicited strong CD4 + T cell responses 17 . In contrast, these two peptides elicited only modest proliferative responses in WT mice. Further, the T cell receptor (TCR) repertoire used for recognition of these determinants by T cells from AQP4 -/-mice was unique. Collectively, these findings indicate that T cell recognition of AQP4 is regulated by thymic negative selection.
well plate. Maintain cultures in a humidified incubator at 37 °C with 5% CO 2 for 72 h. 4. Visually check the LN cells in culture for activation at 48 h and 72 h. Activated cells will form extensive clusters and the T cells will increase in size, becoming more pleomorphic. The increase in metabolism will cause a lowering of the pH in the media, changing from peach to orange. If the pH is low enough to turn the media yellow, add 1 mL of fresh TCM to prevent toxicity to the cells in the remaining 24 h. 5. Proceed to Section 6 for adoptive transfer. Polarization efficiency may be verified by intracellular cytokine staining (ICS), as described in Section 5.
6. Set up cultures using LN from individual mice for flow cytometric analysis of surface Vβ expression (Section 4).
Prepare 5 x 10
6 LN cells per mL with 10 µg/mL Ag in TCM.
2. Add 2 mL (1 x 10 7 cells) of the culture per well into a 12-well plate. Cultures should be maintained in a humidified incubator at 37 °C with 5% CO 2 for 10 days. Proceed to Section 4.
Proliferation Assay
NOTE: This continues from Section 2.4. 
Adoptive Transfer of Pathogenic AQP4-specific T cells
NOTE: This step follows from Section 2.5: T cell culture and proinflammatory T cell polarization. 
Clinical Assessment of ATCA
1. Examine recipient mice daily for clinical signs of CNS autoimmunity. In general, mice will show signs of CNS autoimmunity 5-8 days after adoptive transfer of AQP4-specific T cells. The mice will show clinical symptoms of neurological dysfunction. It is helpful to perform the evaluations on a naive mouse to define the normal ability of a mouse. 2. Evaluate mice for loss of tail tone. Hold the mice gently at the base of the tail and lift upright. A tail that droops continuously is described as loss of tail tone (score of 1). Loss of tail tone is often the first sign of clinical disease. 3. Test for righting reflex by placing mouse on its back on a flat surface. Slow righting is a sign of truncal incoordination (score of 2). A naïve mouse will completely resist any attempt to place it on its back, so any slowness in the ability to right is scored as a dysfunction. It is typical to test the mouse 3-4 times for this reflex. 4. Evaluate posture and ambulation. Mice begin to show a change in posture resulting in a lowering or dragging of the hips during ambulation (score of 2.5). Further disease results in monoplegia, complete paralysis of one hind limb (score of 3.0) and paraplegia, full paralysis of both hind limbs (score of 3.5). Moderate quadraparesis, weakness of all four extremities, results in very slow forward movement (score of 4). Severe quadraparesis allows almost no forward movement (score of 4.5). Finally, with severe disease they may become moribund or die (score of 5). 5. Administer to mice that lose the ability to acquire fluid or solid food 1 mL of 5% glucose in saline i.p. Alternatively, use supplementation with fluid gel cups, high caloric gel and bacon softies to counteract dehydration and food deprivation. Euthanize moribund mice.
Tissue Preparation and Histology
1. Anesthetize mice with 100 mg/kg ketamine and 10 mg/kg xylazine, and then pin each footpad to a dissection board. 2. Open up the chest, exposing the heart. Incise the liver to permit blood outflow. Attach a butterfly needle to the tubing of a miniflow variable speed pump using a separate reservoir for PBS and 10% formalin. Insert the needle into the left ventricle of the heart and perfuse with 5 mL of PBS, followed by 25 mL of 10% formalin.
1. Five min prior to imaging, dilate pupils with 1% tropicamide (one drop per eye) and place mouse to be imaged in the anesthesia induction chamber, providing a steady flow of 2 liters per min (1.5% isoflurane). Turn on heat mat and prepare the post-anesthesia recovery cage. 2. Place the mouse on the imaging cylinder and redirect the anesthesia flow accordingly. Protect eyes with 0.3% hydroxypropyl methylcellulose to keep the eye moist and to ensure refraction continuity. Place a custom contact lens on the eye to be examined. 3. Guided by the infra-red fundus image, direct the laser to the eye, ensuring the beam is centered on the optic nerve head. Vertical and horizontal OCT scans should confirm that the retina lays perpendicular to the laser. 4. Perform 25 B-scans in high-resolution mode and rasterize from 30 averaged A-Scans. 5. After imaging both eyes, remove contact lens and apply ophthalmic gel. Leave mouse in the warm recovery cage. 
Processing and Analysis of OCT

Calculate IRL thicknesses using the Early Treatment Diabetic Retinopathy Study (ETDRS)
2 grid with diameters of 1, 2, and 3 mm centered on the optic disc, and export into a spreadsheet file. The software calculates thickness of each retinal layer by averaging each grid sector. Therefore, the central segment, corresponding to the optic nerve head, is excluded. 3. Analyze statistical differences between groups at each time point. Analyze both eyes for each mouse, using generalized estimating equations with an exchangeable correlation matrix and adjustments for intra-subject inter-eye correlations 21 .
Representative Results
In this protocol, we used donor T cells from C57BL/6 AQP4 -/-mice. Subcutaneous immunization of these mice with AQP4 p135-153 or p201-220, which contain pathogenic T cell epitopes, elicited strong proliferative T cell responses in draining lymph nodes (Figure 1 ), whereas these two peptides induced much weaker T cell proliferation in WT mice. In comparison, immunization with AQP4 p91-110, containing a non-pathogenic AQP4 T cell determinant 13 , or MOG p35-55, a myelin peptide that activates T cells that cause experimental autoimmune encephalomyelitis (EAE) 22, 23, 24 , induced similar magnitude of T cell proliferation in AQP4 -/-and WT mice. Analysis of TCR utilization by flow cytometry staining for individual Vβ's or Vβ families, demonstrated that p135-153-and p201-220-specific T cells from AQP4 -/-mice utilized unique TCR repertoires.
Selective hyper-proliferation of AQP4 p135-153 and p201-220 in AQP4 -/-mice, as well as the unique TCR utilization (Figure 2) , indicated that pathogenic T cell responses to these determinants is normally regulated by thymic negative selection, underscoring the importance for using AQP4 -/-donor T cells in this protocol.
Prior to adoptive transfer for induction of ATCA, lymph node cells from AQP4 peptide-primed mice were cultured in vitro in Th17-or Th1-polarizing conditions for three days. The extent of polarization of donor CD4 + T cells was confirmed by intracellular cytokine staining (ICS) and measured by flow cytometry (Figure 3) . Naïve recipient mice were injected intravenously with 2 x 10 7 donor AQP4 peptide-specific T cells. After approximately six days, nearly 100% of recipient mice developed clinical signs of CNS autoimmune disease, including limp tail and hind limb paralysis (Figure 4) . Th17-polarized AQP4-specific T cells induced more severe clinical disease than Th1-polarized AQP4-specific T cells. A representative mouse that received Th17 AQP4-peptide-specific and developed complete hind limb paralysis (paraplegia) is shown in Video 1.
In contrast with mice that developed EAE after administration of MOG-specific Th17 cells, recipient mice recovered from clinical disease induced by AQP4-specific Th17 cells. As for EAE induced by MOG p35-55-specific Th17 cells, clinical disease induced by AQP4 p135-153-specific or p201-220-specific Th17 cells was associated with infiltration of mononuclear cells in the CNS parenchyma and meninges ( Figure 5 ). Lesions were more abundant in the meninges than in the parenchyma for CNS autoimmunity induced by AQP4-specific Th17 cells. . Then, it was recognized that it would be important to establish an AQP4-targeted animal model of CNS autoimmunity. Such a model could be useful to investigate how AQP4-specific T and B cells participate in development of CNS autoimmunity and to test candidate therapeutics for NMO. Although identification of AQP4-specific T cell epitopes in wildtype mice was first reported in 2010 13 , T cells responding to those epitopes did not cause clinical or histologic disease 14, 17 . The inability to generate a model of CNS autoimmunity based upon immune reactivity to AQP4 remained an enigma until 2015 when Jones, et al. 25 discovered
. Only one other AQP4 amino acid sequence, 201-220, is predicted to bind I-A b with similar high affinity. Indeed, we observed that AQP4 p135-153 and p201-220 both elicit robust proliferation in AQP4 -/-, but not WT, mice. Here, we have shown how one can isolate and expand encephalitogenic Th17 AQP4 p135-153-and p201-220-reactive T cells from AQP4 -/-mice. When transferred into WT recipient mice, donor AQP4-reactive Th17 cells induced paralysis, which was accompanied by mononuclear cell infiltrates in spinal cord and optic nerve. Afferent visual system injury is well known in patients with AQP4-seropositive NMOSD 26 . Here, we observed that optic nerve inflammation induced by AQP4-reactive and MOG-reactive Th17 cells was distinct. Whereas AQP4-specific Th17 cells induced optic perineuritis, MOG-specific Th17 cells induced severe optic neuritis. We have also described the techniques used to monitor optic nerve inflammation induced by AQP4-specific and MOG-specific T cells by serial OCT. Other investigators should now be able to apply the protocols described here to advance their own studies focused on pathogenic mechanisms of ATCA.
One can easily avoid three potential pitfalls in our protocol. First, adoptive transfer of ATCA requires use of AQP4-specific T cells from AQP4 -/-donor mice. Specifically, donor WT AQP4 p135-153-specific T cells did not cause ATCA in recipient WT mice. Secondly, it is important to perform a "water-test" with a drop of the peptide/CFA emulsion before immunization of AQP4 -/-mice (Protocol Step 1.5). The emulsion should not disperse in water when it is suitable for s.c. injection. If the emulsion disperses, one should mix the emulsion once more, chill again and repeat the water-test. Lastly, activated donor CNS antigen-specific T cells induce CNS autoimmunity more efficiently than resting T cells. One should visually inspect those cultures under the light microscope prior to harvesting the donor T cells for adoptive transfer. Rapidly dividing cells may form clusters, which are easily identified. Also, when cultures contain many activated T cells, the media may transition from pink to orange or even to yellow, due to reduction in pH. One can also assess activation of donor AQP4-primed lymph node T cells for proliferation by 3 Hthymidine incorporation, as described in Protocol Step 3.
Our discovery that the two pathogenic AQP4 T cell epitopes are (1) predicted to bind MHC II with high affinity and (2) elicit potent proliferative responses in AQP4 -/-, but not WT, mice suggest that T cells targeting those determinants are normally controlled by thymic negative selection 17 . The TCR repertoires utilized for recognition of AQP4 p135-153 and p201-220 in AQP4 -/-mice are unique (Figure 2 ), which is also consistent with clonal deletion mediated by thymic medullary epithelial cells. Other tolerogenic mechanisms may normally restrain immune responses to AQP4. Subsequent to our initial report 17 , another group also demonstrated that AQP4 p201-220 contains an encephalitogenic T cell determinant 27 . When α/β (TCRα -/-) T cell-deficient mice were reconstituted with AQP4
-/-CD4 + T cells, it was possible to elicit an encephalitogenic AQP4-specific T cell response, but not an AQP4-specific humoral response, implying that in WT mice AQP4-specific B cell responses, similar to AQP4-specific T cell responses, are subject to negative selection. Indeed, loss of spinal cord axons and RGCs, which was not observed in WT mice with ATCA induced by AQP4-specific T cells alone, may require participation of pathogenic AQP4-specific antibodies. It is clear that mouse models of AQP4-targeted CNS autoimmunity will continue to evolve as we learn more regarding the tolerogenic mechanisms normally controlling AQP4-specific T cell and B cell immunity.
Other models of AQP4-targeted CNS autoimmunity are also being developed 6, 16, 28, 29, 30 . Each one may offer advantages for studying particular aspects that are relevant to NMO pathogenesis. AQP4-specific T cells have been identified in WT rats 6, 16, 29 . Those AQP4-specific T cells caused histologic changes of CNS autoimmunity but, similar to observations in mice, WT rat AQP4-specific T cells do not cause significant signs of clinical disease. Therefore, the mechanisms of tolerance restricting T cell and B cell AQP4-specific immune responses in WT mice are also operational in rats. Regardless, one should not underestimate the power in using mouse models for studying mechanisms involved in pathogenesis of disease. The wealth of knock-out, transgenic and reporter mice can be advantageous. It should also be recognized that several fundamental discoveries in autoimmunity were made using mouse EAE models. For example, demonstration that T cell clones specific for a self-antigen can mediate autoimmune disease 31, 32 , identification of the role of T cell costimulation in autoimmunity 33 and the discovery of the developmental pathway for Th17 differentiation 34 were first described using mouse EAE models. Using the mouse model of ATCA that we have developed, one now has the means to study development and regulation of pathogenic AQP4-specific immune responses in vivo, which should provide important insights related to NMO pathogenesis. 
